BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E20.06 EPS (ttm)9.76 Insider Own0.10% Shs Outstand147.10M Perf Week2.43%
Market Cap27.97B Forward P/E12.18 EPS next Y16.07 Insider Trans0.00% Shs Float145.43M Perf Month-12.25%
Income1.45B PEG- EPS next Q4.04 Inst Own85.60% Short Float1.40% Perf Quarter-8.78%
Sales10.82B P/S2.59 EPS this Y-58.10% Inst Trans-1.50% Short Ratio1.82 Perf Half Y-25.17%
Book/sh76.43 P/B2.56 EPS next Y3.48% ROA6.10% Target Price242.00 Perf Year-30.54%
Cash/sh26.25 P/C7.46 EPS next 5Y-8.80% ROE13.40% 52W Range187.16 - 468.55 Perf YTD-18.43%
Dividend- P/FCF9.17 EPS past 5Y-9.30% ROI15.30% 52W High-58.23% Beta0.44
Dividend %- Quick Ratio1.70 Sales past 5Y-0.80% Gross Margin78.00% 52W Low4.57% ATR7.22
Employees9610 Current Ratio2.00 Sales Q/Q-6.00% Oper. Margin22.90% RSI (14)43.28 Volatility2.81% 3.48%
OptionableYes Debt/Eq0.65 EPS Q/Q-23.60% Profit Margin13.40% Rel Volume1.07 Prev Close195.71
ShortableYes LT Debt/Eq0.56 EarningsMay 03 BMO Payout0.00% Avg Volume1.12M Price195.71
Recom2.30 SMA20-3.51% SMA50-5.28% SMA200-21.65% Volume0 Change0.00%
Apr-18-22Upgrade Wells Fargo Equal Weight → Overweight $235 → $265
Mar-08-22Downgrade Stifel Buy → Hold $304 → $223
Mar-03-22Upgrade RBC Capital Mkts Sector Perform → Outperform $227 → $248
Feb-04-22Reiterated Wolfe Research Peer Perform $244 → $217
Feb-04-22Reiterated Wells Fargo Equal Weight $284 → $235
Feb-04-22Reiterated Wedbush Neutral $195 → $185
Feb-04-22Reiterated Robert W. Baird Neutral $258 → $224
Feb-04-22Reiterated RBC Capital Mkts Sector Perform $225 → $227
Feb-04-22Reiterated Oppenheimer Outperform $350 → $285
Feb-04-22Reiterated Needham Buy $292 → $290
Feb-04-22Reiterated Morgan Stanley Overweight $360 → $330
Feb-04-22Reiterated Cowen Outperform $375 → $285
Feb-04-22Reiterated BofA Securities Neutral $245 → $230
Feb-04-22Reiterated Barclays Equal Weight $244 → $235
Feb-04-22Downgrade BMO Capital Markets Outperform → Market Perform $260 → $238
Jan-13-22Downgrade Guggenheim Buy → Neutral $290 → $202
Jan-12-22Downgrade Piper Sandler Overweight → Neutral $362 → $216
Dec-10-21Resumed Raymond James Mkt Perform
Dec-09-21Resumed Wells Fargo Equal Weight $250
Dec-06-21Initiated Goldman Neutral $271
May-16-22 02:05PM  
May-13-22 01:46PM  
May-12-22 05:24AM  
May-10-22 04:13PM  
02:05PM  
11:41AM  
06:20AM  
May-09-22 07:31PM  
May-07-22 10:30AM  
May-06-22 06:07AM  
May-05-22 11:45AM  
11:32AM  
07:38AM  
07:30AM  
06:00AM  
May-04-22 01:39PM  
02:37AM  
May-03-22 03:04PM  
11:18AM  
10:55AM  
10:20AM  
09:48AM  
09:45AM  
08:25AM  
08:10AM  
07:54AM  
07:45AM  
07:21AM  
07:10AM  
May-02-22 03:55PM  
12:58PM  
07:52AM  
06:30AM  
06:22AM  
Apr-29-22 02:34PM  
11:20AM  
07:43AM  
Apr-28-22 05:50PM  
05:26AM  
Apr-27-22 06:00PM  
12:44PM  
08:35AM  
Apr-26-22 03:01PM  
08:03AM  
Apr-22-22 12:22PM  
12:01PM  
10:44AM  
09:41AM  
09:25AM  
Apr-21-22 06:00PM  
10:53AM  
10:37AM  
10:13AM  
Apr-19-22 12:10PM  
Apr-18-22 04:03PM  
Apr-17-22 07:00AM  
Apr-14-22 06:00PM  
03:38PM  
02:11PM  
Apr-13-22 07:36AM  
Apr-11-22 12:01PM  
Apr-08-22 05:50PM  
05:33PM  
04:06PM  
03:57PM  
02:33PM  
01:50PM  
11:15AM  
10:01AM  
09:56AM  
08:59AM  
04:00AM  
Apr-07-22 10:42PM  
09:04PM  
07:53PM  
06:21PM  
05:33PM  
05:21PM  
Apr-04-22 06:00PM  
04:06PM  
12:21PM  
06:20AM  
Apr-02-22 06:43PM  
Mar-31-22 12:19PM  
Mar-30-22 05:15PM  
01:29PM  
07:46AM  
07:30AM  
07:30AM  
Mar-29-22 01:03PM  
11:44AM  
10:27AM  
05:45AM  
05:30AM  
Mar-28-22 06:00PM  
10:13AM  
07:30AM  
Mar-25-22 05:27PM  
Mar-22-22 01:45PM  
11:15AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vounatsos MichelChief Executive OfficerFeb 18Option Exercise0.006,191070,007Feb 23 04:21 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 18Option Exercise0.001,98105,404Feb 23 04:19 PM
Izzar RachidHead of Alzheimer's DiseaseFeb 18Option Exercise0.0059401,929Feb 23 04:16 PM
Kramer RobinChief Accounting OfficerFeb 18Option Exercise0.0039601,854Feb 23 04:18 PM
Murphy NicoleHead of Pharm Ops and TechFeb 18Option Exercise0.0037101,768Feb 23 04:20 PM
Guindo ChirfiHead of Glob Prod Strat & ComFeb 18Option Exercise0.001,98108,243Feb 23 04:15 PM
Gregory GingerEVP, Human ResourcesFeb 18Option Exercise0.001,387011,835Feb 23 04:15 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 18Option Exercise0.001,485045,587Feb 23 04:14 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.002,280045,646Feb 15 04:17 PM
Guindo ChirfiHead of Glob Prod Strat & ComFeb 12Option Exercise0.002,59708,044Feb 15 04:15 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,672011,422Feb 15 04:16 PM
Kramer RobinChief Accounting OfficerFeb 12Option Exercise0.0027501,594Feb 15 04:13 PM
Izzar RachidHead of Alzheimer's DiseaseFeb 12Option Exercise0.0035101,457Feb 15 04:14 PM
Murphy NicoleHead of Pharm Ops and TechFeb 12Option Exercise0.0026301,489Feb 15 04:11 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.008,716070,465Feb 15 04:12 PM
Kramer RobinChief Accounting OfficerDec 03Option Exercise223.9233975,9091,210Dec 07 04:09 PM
Izzar RachidHead of Alzheimer's DiseaseDec 02Option Exercise228.5237285,0091,271Dec 06 04:14 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise338.246,0052,031,1314,864Sep 03 04:08 PM
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM